Ginkgo biloba extract EGb 761® in the treatment of dementia: a pharmacoeconomic analysis of the Austrian settingGinkgo-biloba-Extrakt EGb 761® in der Behandlung der Demenz: eine pharmakoökonomische Analyse bezogen auf Österreich

被引:0
作者
Michael Rainer
Hermann Mucke
Sandra Schlaefke
机构
[1] Sozialmedizinisches Zentrum Ost – Donauspital,Department of Psychiatry, Memory Clinic
[2] Karl-Landsteiner-Institut für Gedächtnis- und Alzheimer-Forschung,Clinical Research Department
[3] H.M. Pharma Consultancy,undefined
[4] Dr. Willmar Schwabe GmbH & Co. KG,undefined
关键词
Dementia; Ginkgo biloba; EGb 761®; Economics; Pharmaceutical; Austria; Demenz; Ginkgo biloba; EGb 761®; Pharmakoökonomie; Österreich;
D O I
10.1007/s00508-012-0307-x
中图分类号
学科分类号
摘要
引用
收藏
页码:8 / 15
页数:7
相关论文
共 47 条
[1]  
Kleijnen J(1992)Ginkgo biloba for cerebral insufficiency Br J Clin Pharmacol. 34 352-8
[2]  
Knipschild P(2002)Pharmaco-economic evaluation of Ginkgo special extract EGb 761® for dementias in Austria Wien Med Wochenschr. 152 427-31
[3]  
Hörr R(2004)Delay in progression of dependency and need of care of dementia patients treated with Ginkgo special extract EGb 761® Wien Med Wochenschr. 154 511-4
[4]  
Kieser M(2007)Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial Arzneimittelforschung. 57 4-11
[5]  
Haan J(2011)Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomized controlled trial Int J Geriatr Psychiatry. 26 1186-94
[6]  
Hörr R(2012)Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomized, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg J Psychiatr Res. 46 713-23
[7]  
Napryeyenko O(1994)Factors affecting course and survival in Alzheimer’s disease. A 9-year longitudinal study Arch Neurol. 51 1213-9
[8]  
Borzenko I(1996)The consortium to establish a registry for Alzheimer’s disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer’s disease Neurology. 46 656-60
[9]  
Ihl R(1999)The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease Arch Neurol. 56 1388-93
[10]  
Bachinskaya N(1997)Validity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative Study Alzheimer Dis Assoc Disord. 11 S22-300